Ariad Pharmaceuticals: PharmaVitae Report

Introduction

Introduction

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Features and benefits

• Gain insight into Ariad Pharmaceuticals' strategic outlook
• Analyze company sales forecasts by product

Highlights

Ariad's most advanced product candidate is ponatinib, which the company believes has potential in hematological cancers and solid tumors. It is in a pivotal Phase II trial and Ariad plans to file for marketing approval of ponatinib in the US and Europe in the third quarter of 2012.

Ariad's second-closest product to approval is AP26112, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). These are both targets in non-small cell lung cancer (NSCLC). Depending on the outcome of a Phase I/II trial, Ariad envisions starting a pivotal trial in NSCLC patients in 2013.

Your key questions answered

• Benchmark Ariad Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sector
• Assess how successful Ariad Pharmaceuticals will be in obtaining marketing approval for its first product

Table of Contents

ABOUT THIS REPORT

• PharmaVitae Explorer database

• Chapter structure
  • Sales and product analysis
  • Financial analysis

• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Company introduction
  • Recent developments
  • Corporate relationships

• Strategic overview

• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

SALES AND PRODUCT ANALYSIS

• Sales overview

• Product analysis
  • Product sales

• Ponatinib
  • Chronic myeloid leukemia
  • Acute lymphoblastic leukemia
  • Current treatments: marketed drugs for CML do not have activity against the T315I mutation
  • Current treatments: first-line treatment of ALL consists of combination chemotherapy regimens
  • Clinical trials
  • Factors affecting ponatinib approval and use
  • Key forecasting assumptions

• Other products
  • Ridaforolimus

FINANCIAL ANALYSIS

• Financial performance overview
  • Operating costs and profit analysis, 2005 - 11
  • Operating costs and profit analysis, 2011 - 17

APPENDIX

• References
  • Datamonitor reports

• Exchange rates

• Table: Ariad Pharmaceuticals product portfolio overview ($m), 2012 - 17
• Table: Ariad Pharmaceuticals' clinical trial program includes one pivotal Phase II trial and a planned Phase III trial
• Table: Phase II PACE trial data with ponatinib
• Table: Ponatinib US sales forecast model
• Table: Ponatinib EU sales forecast model
• Table: Ariad operating revenue/cost analysis ($m), 2005 - 11
• Table: Ariad operating revenue/cost analysis ($m), 2011 - 17
• Table: Exchange rates, 2011

• Figure: PharmaVitae Explorer
• Figure: Ariad prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012 - 17
• Figure: Ariad Pharmaceuticals key product sales ($m), 2012 - 17
• Figure: Ariad Pharmaceuticals operating/cost performance ($m), 2005 - 17

Ariad Pharmaceuticals: PharmaVitae Report published by Datamonitor in June 6, 2012. This report consists of Pages: 34 and the price starts from US $ 5700.